18 and older, female only, with Gestational Weight Gain. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Intervention Satisfaction Observed From Follow-up SurveyPrimary· Up to 32 weeks
At 32 weeks gestation participants will be asked to offer insight into program acceptability in each condition, as well as satisfaction to the program in general by answering an internet-based survey, that was developed for this study (not a standardized scale). The investigators will examine participants' survey responses regarding participants' satisfaction of the program (items are scored on a scale from 1 to 5, with 5 being the most positive).
How much would you recommend using an e-scale for managing GWG to a friend?
Group
Value
95% CI
Lottery + Monthly Weight
5
5 – 5
Lottery + Overall Weight + Exercise
4.25
3 – 5
Lottery + Overall Weight
4.25
2 – 5
Lottery + Monthly Weight + Exercise
5
5 – 5
Loss + Monthly Weight
4.8
4 – 5
Loss + Overall Weight + Exercise
4.75
4 – 5
Loss + Overall Weight
4.8
4 – 5
Loss + Monthly Weight + Exercise
4.8
4 – 5
How much would you recommend using a fitness tracker for managing GWG to a friend?
Group
Value
95% CI
Lottery + Monthly Weight
4.67
4 – 5
Lottery + Overall Weight + Exercise
3.5
2 – 5
Lottery + Overall Weight
5
5 – 5
Lottery + Monthly Weight + Exercise
5
5 – 5
Loss + Monthly Weight
4.4
2 – 5
Loss + Overall Weight + Exercise
4.25
3 – 5
Loss + Overall Weight
4.6
4 – 5
Loss + Monthly Weight + Exercise
4.4
3 – 5
How much would you recommend setting a weight gain goal for managing GWG to a friend?
Group
Value
95% CI
Lottery + Monthly Weight
4.67
4 – 5
Lottery + Overall Weight + Exercise
4.25
3 – 5
Lottery + Overall Weight
4.5
3 – 5
Lottery + Monthly Weight + Exercise
5
5 – 5
Loss + Monthly Weight
4.4
3 – 5
Loss + Overall Weight + Exercise
4.75
4 – 5
Loss + Overall Weight
4.8
4 – 5
Loss + Monthly Weight + Exercise
4.6
4 – 5
How much would you recommend setting a physical activity goal for managing GWG to a friend?
Group
Value
95% CI
Lottery + Monthly Weight
4
3 – 5
Lottery + Overall Weight + Exercise
4.25
3 – 5
Lottery + Overall Weight
4.5
3 – 5
Lottery + Monthly Weight + Exercise
5
5 – 5
Loss + Monthly Weight
5
5 – 5
Loss + Overall Weight + Exercise
4.25
3 – 5
Loss + Overall Weight
4.8
4 – 5
Loss + Monthly Weight + Exercise
4.8
4 – 5
Recruitment Yields Observed From Enrollment SurveyPrimary· Up to 36 weeks
The number of participants initially recruited for the study will be closely monitored.
Group
Value
95% CI
Lottery + Monthly Weight
4
Lottery + Overall Weight + Exercise
5
Lottery + Overall Weight
5
Lottery + Monthly Weight + Exercise
5
Loss + Monthly Weight
5
Loss + Overall Weight + Exercise
5
Loss + Overall Weight
5
Loss + Monthly Weight + Exercise
5
Program Retention Observed From Enrollment and Followup SurveysPrimary· Up to 36 weeks
The number of participants stayed in the study within the time frame of the study will be closely monitored.
Group
Value
95% CI
Lottery + Monthly Weight
3
Lottery + Overall Weight + Exercise
4
Lottery + Overall Weight
4
Lottery + Monthly Weight + Exercise
5
Loss + Monthly Weight
5
Loss + Overall Weight + Exercise
4
Loss + Overall Weight
5
Loss + Monthly Weight + Exercise
5
Gestational Weight Gain Observed From Weight Recorded at Baseline and up to 36 WeeksSecondary· Up to 36 weeks
At all measurement visits, weight will be recorded in kilograms on a calibrated research-grade scale. Weight will be measured on a calibrated digital scale in duplicate, with the participant wearing light clothing and no shoes. While we will obtain the mother's weight at baseline, we will also obtain self-reported preconception weight (before the last menstrual period). We will calculate the participant's GWG goal based on self-reported preconception BMI. The difficulty of anticipating when a final weight should be obtained to capture the fullest extent of GWG was considered, and we elected to
Group
Value
95% CI
Lottery + Monthly Weight
13.2
10.0 – 18.0
Lottery + Overall Weight + Exercise
6.8
0.9 – 11.2
Lottery + Overall Weight
8.4
-3.7 – 14.2
Lottery + Monthly Weight + Exercise
9.4
8.1 – 11.2
Loss + Monthly Weight
9.6
-2.1 – 20.1
Loss + Overall Weight + Exercise
8.9
-0.2 – 13.3
Loss + Overall Weight
11.8
3.4 – 18.8
Loss + Monthly Weight + Exercise
11.8
6.9 – 15.0
Number of Participants With Gestational Weight Gain Within IOM RecommendationSecondary· Up to 36 weeks pregnancy
We will evaluate whether participants' final gestational weight gain at Week 32 or Week 36 pregnancy would be under, within, or above IOM's recommendation. The Week 36 weight will be the primary outcome except for mothers who deliver prior to 36 weeks, in which case we will use the Week 32 weight. This is to determine the effect of the intervention on prevention of excess gestational weight gain.
Group
Value
95% CI
Lottery + Monthly Weight
2
Lottery + Overall Weight + Exercise
2
Lottery + Overall Weight
0
Lottery + Monthly Weight + Exercise
1
Loss + Monthly Weight
2
Loss + Overall Weight + Exercise
2
Loss + Overall Weight
1
Loss + Monthly Weight + Exercise
3
Adverse events — posted to ClinicalTrials.gov
Time frame: Baseline to 36 weeks gestation.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Bloom is a research study that examines whether incentives for daily self-weighing, weekly physical activity, monthly weight management or overall (from enrollment up to 36 weeks pregnancy) weight management could help pregnant mothers manage a health weight gain during pregnancy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Tennessee
Last refreshed: 8 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03834194.